Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole vs Placebo in HR+ Breast Cancer After 5 Years of Endocrine Therapy
NCT00382070Phase 3Active, not recruiting
- Sponsor
- NSABP Foundation
- Start
- Aug 2006
- Primary completion
- Aug 2016
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of letrozole in breast cancer, sponsored by NSABP Foundation. Primary endpoint: Disease-free Survival at 7 years. Started Aug 2006; status: active, not recruiting.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00382070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382070.